Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell cycle and induces apoptosis.

Abl:0.21 μM, Abl (E255K):0.53 μM, Abl (T315I):0.64 μM

METHODS: Erythrocytes were treated with Nocodazole (15-60 µg/mL) for 48 h. Phosphatidylserine was detected using Annexin-V-FITC.
RESULTS: Nocodazole treatment increased the percentage of phosphatidylserine exposed to erythrocytes, reaching statistical significance at 30 µg/mL. [1]
METHODS: hESCs cells were treated with Nocodazole (100 ng/mL) for 16 h and cell cycle profiles were analyzed using Flow Cytometry.
RESULTS: Nocodazole treatment synchronized the cell cycle (>90% of cells in G2/M), while cells remained synchronized after release and moved evenly through the cell cycle for 24 h. At 2 h after removal of Nocodazole, the cells entered the G1 phase, with 70% of the cells in the G1 phase after 4 h, and 80% in the S phase after 12 h. The cells were treated with Nocodazole (100 ng/mL) for 16 h, and the cell cycle was analyzed by Flow Cytometry. [2]

METHODS: To detect anti-tumor activity in vivo, Nocodazole (12 mg/kg three times a week) and dexamethasone (2 mg/kg twice a week) were injected intraperitoneally for fifteen days into immunodeficient mice bearing myeloma H929.
RESULTS: Nocodazole in combination with dexamethasone significantly inhibited myeloma tumor growth and prolonged survival. [3]
METHODS: To study the effects on intestinal mucositis, Nocodazole (5 mg/kg) and ketoconazole (50 mg/kg) were administered intraperitoneally three times a week for six weeks to nude mice harboring the human colorectal cancer tumor COLO 205.
RESULTS: The antitumor effect of Nocodazole was significantly enhanced after six weeks of ketoconazole treatment. [4]

Nocodazole is dissolved in a final concentration of 0.05% DMSO. Proteins are loaded at 50 μg/lane and separated by 12% (w:v) sodium dodecyl sulfate-polyacrylamide gel electrophoresis, blotted, and probed with antibodies for cyclin E, p53, p21/CIP1, p27/KIP1, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), cyclin A, cyclin D1, cyclin D3, cyclin B, CDK2, CDK4, and cytochrome C. Immunoreactive bands are visualized by incubating with the colorigenic substrates nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate. The expression of GAPDH is used as the control for equal protein loading.